Compare IVDA & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVDA | DCOY |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.2M |
| IPO Year | 2015 | 2014 |
| Metric | IVDA | DCOY |
|---|---|---|
| Price | $0.31 | $1.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 311.9K | ★ 3.8M |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,468,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.98 | N/A |
| 52 Week Low | $0.21 | $0.53 |
| 52 Week High | $2.15 | $13.51 |
| Indicator | IVDA | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 33.78 |
| Support Level | $0.27 | $0.61 |
| Resistance Level | $0.33 | $3.29 |
| Average True Range (ATR) | 0.02 | 0.70 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 34.02 | 1.22 |
Iveda Solutions Inc offers smart city technologies globally, offering AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products). Geographically, the company operates in USA and Taiwan, majority of its revenue is generated from Taiwan.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.